Clinical Trials · NCT03791736

Evaluation of Impact of Sandostatin® Injection Before Axillary Clearance on Lymphocele Formation

Name: Evaluation of Impact of Sandostatin® Injection Before Axillary Clearance on Lymphocele Formation
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

TerminatedN/AOctreotide

Phase: N/A
Recruitment status: Terminated
Sponsor: Institut Cancerologie de l'Ouest
Enrollment: 4
Start date: Jul 2016
Locations: See registry
Primary endpoint: A 50% decrease in the incidence of lymphocele (30% to 15% progression) following axillary clearance of patients operated for breast cancer (excluding mastectomy) pretreated with an injection of Sandostatin®.

View Octreotide compound reference